March 11, 2022
The nonprofit International Partnership for Microbicides (IPM) today announced that the monthly dapivirine vaginal ring received regulatory approval from the South African Health Products Regulatory Authority (SAHPRA) for its use by women ages 18 and older to reduce their HIV risk. This marks a major milestone that brings the first long-acting and woman-controlled product another step closer to reaching women.
Women bear a disproportionate burden of the global HIV/AIDS epidemic, with nearly two-thirds of new adult infections in South Africa—and across sub-Saharan Africa—occurring among women. In South Africa, every week, nearly 2,700 women ages 15 and older acquire HIV. Expanding women’s HIV prevention choices so that they can choose the method that best meets their individual needs is critical to controlling the epidemic, and ensuring their sexual and reproductive health and rights.
(Article from the Desmond Tutu Health Foundation)
Comments